Vantage logo

Doomsday for Allakos

If lirentelimab reduces eosinophils in diseases characterised by eosinophil accumulation, why doesn’t it work?

Vantage logo

Go or no go? The FDA plays hardball

April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.